Last reviewed · How we verify
Cefepim
At a glance
| Generic name | Cefepim |
|---|---|
| Sponsor | University Hospital Tuebingen |
| Target | Bacterial penicillin-binding protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | discontinued |
Approved indications
- Bacterial infection due to Klebsiella pneumoniae
- Bacterial peritonitis
- Bacterial pneumonia
- Bacterial urinary infection
- Complicated Bacteroides Peritonitis
- Complicated E. Coli Peritonitis
- Complicated Klebsiella Peritonitis
- Complicated Proteus UTI
- Complicated Streptococcus Peritonitis
- Complicated Urinary Tract Infections
- E. Coli Pyelonephritis
- Enterobacter Pneumonia
- Escherichia coli urinary tract infection
- Infection due to Pseudomonas aeruginosa
- Infection due to Staphylococcus aureus
- Infectious disease of abdomen
- Klebsiella Pyelonephritis
- Klebsiella cystitis
- Pneumococcal pneumonia
- Pneumonia due to Pseudomonas
Common side effects
Key clinical trials
- Pharmacokinetics and Pharmacodynamic (PK/PD) of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock (Phase 3)
- A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Includin (Phase 3)
- A Multicenter, Open-label, Randomized, Active-controlled, Parallel Group, Pivotal Study to Investigate the Efficacy, Safety and Tolerability, and Pharmacokinetics of Murepavadin Combined With One Anti (Phase 3)
- Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Haematologic Patients: a Randomised, Multicentre, Open-label, Superiority Clinical Trial (BEATLE) (Phase 4)
- Randomized, Double-Blind, Multi-Center Study of Cefepime/AAI101 in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis (Phase 2)
- Pharmacodynamic Parameters of Two Different Doses of Cefepime (N/A)
- A Study to Evaluate the Predictive Performance of a Target-controlled Infusion Model for the Administration of Cefepime to Intensive Care Patients (NA)
- Cefepime vs. Carbapenems for Treating AmpC β-lactamase-producing Enterobacteriaceae Bloodstream Infections (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |